Research programme: anticancer therapeutics - Affichem

Drug Profile

Research programme: anticancer therapeutics - Affichem

Alternative Names: AF 122; AFF 354; DDA; Dendrogenin A

Latest Information Update: 18 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AFFICHEM
  • Developer Affichem
  • Class Small molecules; Sterols
  • Mechanism of Action Cell differentiation stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Colorectal cancer; Leukaemia; Malignant melanoma

Most Recent Events

  • 18 Jul 2011 Preclinical development is ongoing in France
  • 18 Jul 2011 This programme is still available for licensing as of 18 Jul 2011. http://www.affichem.com
  • 14 May 2009 The programme is available for partnering (http://www.affichem.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top